A Phase 1 interventional study of Linaprazan glurate in Safety, Bioavailability and Pharmacokinetics, sponsored by Cinclus Pharma Holding AB. Completed at 1 site in Slovenia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-03.
Sponsored by Cinclus Pharma Holding AB · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-center, open-label, randomized, single dose, 3-way crossover study in healthy volunteers designed to evaluate the relative bioavailability of a new oral tablet formulation of linaprazan glurate in comparison to a previously studied oral tablet formulation under fasting conditions, and to assess the effect of a high fat, high calorie meal on the pharmacokinetics (PK) of linaprazan glurate and the active substance linaprazan after the administration of the new oral tablet formulation.
Cinclus Pharma Holding AB is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 mg linaprazan glurate reference formulation (4x25 mg oral tablets) in fasting conditions
Drug: Linaprazan glurate
100 mg linaprazan glurate test formulation (1x100 mg oral tablet) in fasting conditions
Drug: Linaprazan glurate
100 mg linaprazan glurate test formulation (1x100 mg oral tablet) in fed conditions
Drug: Linaprazan glurate
100 mg
Also known as: formerly X842
Relative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratios of AUCinf and AUClast
The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprazan, comparing test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan exposure is increased or decreased with the new formulation.
Time frame: From pre-dose up to 72 h post dose
Relative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratio of Cmax
The Ratio of Cmax (highest measured concentration) of linaprazan comparing the test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan exposure is increased or decreased with the new formulation.
Time frame: From pre-dose up to 72 h post dose
Relative Bioavailability of Linaprazan Test Formulation in Fed vs. Fasting Conditions, Based on the Means Ratios for AUCinf and AUClast
The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprazan, comparing test formulation vs reference formulation (treatments C vs treatment B) for Relative Bioavailability, i.e. how much linaprazan exposure is increased or decreased in a fed vs fasted state.
Time frame: From pre-dose up to 72 h post dose
Relative Bioavailability of Linaprazan Test Formulation in Fed vs. Fasting Conditions, Based on the Means Ratios for Cmax
The Ratio of Cmax of linaprazan when comparing test formulation vs reference formulation (treatments C vs treatment B), i.e. how much linaprazan exposure is increased or decreased with the new formulation.
Time frame: From pre-dose up to 72 h post dose
Relative Bioavailability of Linaprazan Glurate for the Test Formulation vs. Reference Formulation of Linaprazan Glurate, Based on the Means Ratios of PK Parameters.
The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprzan glurate, comparing test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan glurate exposure is increased or decreased with the new formulation.
Time frame: From pre-dose up to 72 h post dose
Relative Bioavailability of Linaprazan Glurate Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratio of Cmax
The Ratio of Cmax (highest measured concentration) of linaprazan glurate comparing the test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan glurate exposure is increased or decreased with the new formulation.
Time frame: From pre-dose up to 72 h post dose
Relative Bioavailability of Linaprazan Glurate in Fed vs. Fasting Conditions, Based on the Means Ratios for AUCinf, AUClast
The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprazan glurate, comparing test formulation vs reference formulation (treatments C vs treatment B) for Relative Bioavailability, i.e. how much linaprazan glurate exposure is increased or decreased in a fed vs fasted state.
Time frame: From pre-dose up to 72 h post dose
Relative Bioavailability of Linaprazan Glurate in Fed vs. Fasting Conditions, Based on the Means Ratio of Cmax
The Ratio of Cmax of linaprazan glurate when comparing test formulation vs reference formulation (treatments C vs treatment B), i.e. how much linaprazan glurate exposure is increased or decreased with the new formulation.
Time frame: From pre-dose up to 72 h post dose
Subjects were recruited form CRS's database of healthy volunteers. All Volunteers were recruited in Slovenia, Ljubljana.
| Milestone | Treatment Sequence A B C | Treatment Sequence A C B | Treatment Sequence B A C | Treatment Sequence B C A | Treatment Sequence C A B | Treatment Sequence C B A | Exploratory Arm A B C | Exploratory Arm A C B |
|---|---|---|---|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 | 9 | 9 | 6 | 7 |
| Completed | 9 | 9 | 7 | 9 | 9 | 8 | 0 | 0 |
| Not completed | 0 | 0 | 2 | 0 | 0 | 1 | 6 | 7 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 |
| Milestone | Treatment Sequence A B C | Treatment Sequence A C B | Treatment Sequence B A C | Treatment Sequence B C A | Treatment Sequence C A B | Treatment Sequence C B A | Exploratory Arm A B C | Exploratory Arm A C B |
|---|---|---|---|---|---|---|---|---|
| Started | 9 | 9 | 7 | 9 | 9 | 8 | 0 | 0 |
| Completed | 7 | 9 | 7 | 9 | 9 | 8 | 0 | 0 |
| Not completed | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence A B C | Treatment Sequence A C B | Treatment Sequence B A C | Treatment Sequence B C A | Treatment Sequence C A B | Treatment Sequence C B A | Exploratory Arm A B C | Exploratory Arm A C B |
|---|---|---|---|---|---|---|---|---|
| Started | 7 | 9 | 7 | 9 | 9 | 8 | 0 | 0 |
| Completed | 7 | 9 | 7 | 9 | 9 | 8 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprazan, comparing test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan exposure is increased or decreased with the new formulation.
| hours * nmol/Liter | Reference Formulation (Treatment A) | Test Formulation (Treatment B) |
|---|---|---|
| AUCinf | 12341 ± 1.51 | 25001 ± 1.32 |
| AUClast | 10016.2 ± 2.78 | 24175.8 ± 1.34 |
The Ratio of Cmax (highest measured concentration) of linaprazan comparing the test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan exposure is increased or decreased with the new formulation.
| nmol/L | Reference Formulation (Treatment A) | Test Formulation (Treatment B) |
|---|---|---|
| Relative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratio of Cmax | 1430 ± 1.83 | 3462.2 ± 1.25 |
The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprazan, comparing test formulation vs reference formulation (treatments C vs treatment B) for Relative Bioavailability, i.e. how much linaprazan exposure is increased or decreased in a fed vs fasted state.
| hours * nmol/Liter | Test Formulation (Treatment B) | Test Formulation (Treatment C) |
|---|---|---|
| AUCinf | 25001 ± 1.32 | 19448.9 ± 1.32 |
| AUClast | 24175.8 ± 1.34 | 19022.8 ± 1.32 |
The Ratio of Cmax of linaprazan when comparing test formulation vs reference formulation (treatments C vs treatment B), i.e. how much linaprazan exposure is increased or decreased with the new formulation.
| nmol/L | Test Formulation (Treatment B) | Test Formulation (Treatment C) |
|---|---|---|
| Relative Bioavailability of Linaprazan Test Formulation in Fed vs. Fasting Conditions, Based on the Means Ratios for Cmax | 3462.2 ± 1.25 | 1608 ± 1.29 |
The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprzan glurate, comparing test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan glurate exposure is increased or decreased with the new formulation.
| hours * nmol/Liter | Reference Formulation (Treatment A) | Test Formulation (Treatment B) |
|---|---|---|
| AUCinf | 114.2 ± 1.95 | 320.2 ± 1.73 |
| AUClast | 83.9 ± 2.49 | 293 ± 1.84 |
The Ratio of Cmax (highest measured concentration) of linaprazan glurate comparing the test formulation vs reference formulation (treatments B vs treatment A) for Relative Bioavailability, i.e. how much linaprazan glurate exposure is increased or decreased with the new formulation.
| nmol/L | Reference Formulation (Treatment A) | Test Formulation (Treatment B) |
|---|---|---|
| Relative Bioavailability of Linaprazan Glurate Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratio of Cmax | 86.8 ± 2.44 | 214.3 ± 2.08 |
The Ratio of Area Under the plasma concentration vs. time Curve (AUC) from time 0 to infinity (AUCinf), and from time 0 to last measurement (AUClast) of linaprazan glurate, comparing test formulation vs reference formulation (treatments C vs treatment B) for Relative Bioavailability, i.e. how much linaprazan glurate exposure is increased or decreased in a fed vs fasted state.
| hours * nmol/Liter | Test Formulation (Treatment B) | Test Formulation (Treatment C) |
|---|---|---|
| AUCinf | 320.2 ± 1.73 | 166.3 ± 1.52 |
| AUClast | 293.0 ± 1.84 | 144.3 ± 1.62 |
The Ratio of Cmax of linaprazan glurate when comparing test formulation vs reference formulation (treatments C vs treatment B), i.e. how much linaprazan glurate exposure is increased or decreased with the new formulation.
| nmol/L | Test Formulation (Treatment B) | Test Formulation (Treatment C) |
|---|---|---|
| Relative Bioavailability of Linaprazan Glurate in Fed vs. Fasting Conditions, Based on the Means Ratio of Cmax | 214.3 ± 2.08 | 55.0 ± 2.23 |
Collected over Baseline to Visit 5, 1 month. Non-serious events are listed at a 1.40% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reference Formulation (Treatment A) | 0/51 (0%) | 0/51 (0%) | 17/51 (33.3%) |
| Test Formulation (Treatment B) | 0/53 (0%) | 1/53 (1.9%) | 12/53 (22.6%) |
| Test Formulation (Treatment C) | 0/50 (0%) | 0/50 (0%) | 14/50 (28%) |
| Reference | 0/13 (0%) | 0/13 (0%) | 4/13 (30.8%) |
| Event | Reference Formulation (Treatment A) | Test Formulation (Treatment B) | Test Formulation (Treatment C) | Reference |
|---|---|---|---|---|
| Skin Bacterial InfectionSkin and subcutaneous tissue disorders | 0/51 | 1/53 | 0/50 | 0/13 |
| Event | Reference Formulation (Treatment A) | Test Formulation (Treatment B) | Test Formulation (Treatment C) | Reference |
|---|---|---|---|---|
| PapulaSkin and subcutaneous tissue disorders | 0/51 | 0/53 | 0/50 | 2/13 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 1/51 | 0/53 | 0/50 | 2/13 |
| NasopharyngitisInfections and infestations | 3/51 | 0/53 | 4/50 | 0/13 |
| Cardiac disordersCardiac disorders | 4/51 | 3/53 | 1/50 | 0/13 |
| Vascular disordersSkin and subcutaneous tissue disorders | 1/51 | 2/53 | 3/50 | 0/13 |
| TachycardiaCardiac disorders | 3/51 | 3/53 | 1/50 | 0/13 |
| HeadacheNervous system disorders | 3/51 | 1/53 | 2/50 | 0/13 |
| PhlebitisVascular disorders | 0/51 | 1/53 | 2/50 | 0/13 |
| DiarrhoeaGastrointestinal disorders | 2/51 | 0/53 | 0/50 | 0/13 |
| VomitingGastrointestinal disorders | 2/51 | 0/53 | 0/50 | 0/13 |
13 subjects were erroneously underdosed with 1x25 mg LG instead of 4x25 mg in the sequence arms starting with treatment A. These 13 subjects were excluded from the analysis set and replaced. Data was collected nevertheless and presented as "exploratory". This is why there is an imbalance between the number in the first two sequence arms. In addition, in error, one subject recieved the treatments in reverse order from his/her randomization. E.g. B C A instead of as randomized to A C B.
| Age, Categorical(Participants) | Treatment Sequence A B C | Treatment A C B | Treatment B A C | Treatment B C A | Treatment C A B | Treatment C B A | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 15 | 15 | 9 | 10 | 9 | 9 | 67 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Treatment Sequence A B C | Treatment A C B | Treatment B A C | Treatment B C A | Treatment C A B | Treatment C B A | Total |
|---|---|---|---|---|---|---|---|
| Mean | 22.2 (19 to 26) | 24.3 (18 to 35) | 26.4 (19 to 45) | 21.5 (18 to 25) | 29.6 (19 to 48) | 22.3 (19 to 26) | 24.1 (18 to 48) |
| Sex: Female, Male(Participants) | Treatment Sequence A B C | Treatment A C B | Treatment B A C | Treatment B C A | Treatment C A B | Treatment C B A | Total |
|---|---|---|---|---|---|---|---|
| Female | 7 | 9 | 8 | 2 | 6 | 3 | 35 |
| Male | 8 | 6 | 1 | 8 | 3 | 6 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence A B C | Treatment A C B | Treatment B A C | Treatment B C A | Treatment C A B | Treatment C B A | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 14 | 15 | 9 | 10 | 9 | 9 | 66 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Treatment Sequence A B C | Treatment A C B | Treatment B A C | Treatment B C A | Treatment C A B | Treatment C B A | Total |
|---|---|---|---|---|---|---|---|
| Slovenia | 15 | 15 | 9 | 10 | 9 | 9 | 67 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2022 to primary completion in Dec 2022, 1 month.
Results were first posted in Apr 2025, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linaprazan glurate
Cinclus Pharma Holding AB